4D Molecular grants 219,000 stock options

4D Molecular Therapeutics, Inc. reported that officer Christopher Paul Simms received a grant of stock options covering 219,000 shares of common stock.

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. reported that officer Christopher Paul Simms received a grant of stock options covering 219,000 shares of common stock. The options have an exercise price of $9.88 per share and expire on March 24, 2036.

According to the terms, 1/48 of the underlying shares will vest each month starting on March 25, 2026, so long as Simms remains a service provider, with full vesting on the fourth anniversary of that date. Following this grant, he holds options for 219,000 shares directly.

Insider Trade Summary

Grant/Award: 219,000 shares

Grant/Award 1 txn

Insider Simms Christopher Paul

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	219,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 219,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Christopher Paul Simms receive in this 4D Molecular Therapeutics (FDMT) Form 4?

Christopher Paul Simms received a grant of stock options for 219,000 shares of 4D Molecular Therapeutics common stock. These options were awarded as compensation and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price and term of the new FDMT stock options?

The granted stock options have an exercise price of $9.88 per share and expire on March 24, 2036. This means Simms can choose to exercise the options at that price any time before the expiration date, once the options are vested.

How do the 219,000 FDMT stock options vest for Christopher Paul Simms?

The 219,000 options vest in equal monthly installments over four years. Specifically, 1/48 of the underlying shares vests on each monthly anniversary of March 25, 2026, provided Simms continues as a service provider, leading to full vesting on the fourth anniversary.

How many FDMT options does Christopher Paul Simms hold after this transaction?

After this grant, Simms holds stock options for 219,000 shares of 4D Molecular Therapeutics common stock directly. This Form 4 only reports this new award and shows his derivative holdings reflecting this option position following the transaction.

Is this FDMT Form 4 a stock purchase or a compensation award?

This Form 4 reflects a compensation-related award, not an open-market stock purchase. Simms received stock options at a fixed exercise price, classified as a grant or award acquisition, rather than buying or selling shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simms Christopher Paul

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.88	03/25/2026		A		219,000		(1)	03/24/2036	Common Stock	219,000	$0	219,000	D

Explanation of Responses:

1. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Remarks:

Chief Commercial and Business Officer

	/s/ Scott Bizily as Attorney-in-Fact for Christopher Paul Simms	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)